Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054977 · ClinicalTrials.gov registry record · Phase 1

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

A Phase 1 study, sponsored by Galectin Therapeutics.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00054977: Completed Phase 1 study, sponsored by Galectin Therapeutics.

NCT00054977 is a Phase 1 study that has completed, run by Galectin Therapeutics. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054977, a Phase 1 study, has completed, sponsored by Galectin Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.

Interventions

  • DRUG 5-fluorouracil
  • DRUG GM-CT-01

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2003-02
Est. Completion 2006-09
Phase Phase 1
Galectin Therapeutics

8 total trials

What the finished NCT00054977 record still lists

NCT00054977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which 5-fluorouracil is the first listed.

NCT00054977 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00054977 about?

NCT00054977 is a clinical study titled "Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors". This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients...

What is the current status of trial NCT00054977?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-02. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00054977?

The interventions under investigation include: 5-fluorouracil (DRUG), GM-CT-01 (DRUG).

Who is sponsoring clinical trial NCT00054977?

This trial is sponsored by Galectin Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00054977's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00054977, the US trial registry maintained by the National Library of Medicine. NCT00054977 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.